Immunocore Holdings (IMCR) Net Margin (2021 - 2026)
Immunocore Holdings (IMCR) posted quarterly Net Margin of 12.16% for Q1 2026, up 685.0% year-on-year from 1.55% in Q1 2025, and up 142.26% on a QoQ basis from 28.77% in Q4 2025.
Immunocore Holdings (IMCR) Net Margin (2021 - 2026) Analysis & Trends
Immunocore Holdings (IMCR) has reported Net Margin for 6 consecutive years, with 12.16% the latest figure, recorded in Q1 2026.
- Quarterly Net Margin rose 685.0% year-over-year to 12.16% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6.68% (down 18.0% YoY) and the FY2025 annual result came in at 8.88%, up 759.0% from the prior year.
- Net Margin grew to 12.16% in Q1 2026 per IMCR's latest filing, from 28.77% in the prior quarter.
- Over the last five years, Net Margin for IMCR reached as high as 15.12% in Q3 2022 and fell as low as 52.99% in Q4 2022.
- A 5-year average of 16.75% and a median of 21.77% in 2023 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin surged 54445 bps — and 2023, when it plunged 1372 bps.
- Year by year, Net Margin stood at 52.99% in 2022, then soared by 47 bps to 28.12% in 2023, then dropped by 1 bps to 28.28% in 2024, then declined by 2 bps to 28.77% in 2025, then surged by 142 bps to 12.16% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 12.16%, 28.77%, and 0.19% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Immunocore Holdings | 1.80 Bn | 957.43 Mn | 106.24 Mn | 12.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.16% |
| Dec 31, 2025 | -28.77% |
| Sep 30, 2025 | -0.19% |
| Jun 30, 2025 | -10.51% |
| Mar 31, 2025 | 5.31% |
| Dec 31, 2024 | -28.28% |
| Sep 30, 2024 | 10.89% |
| Jun 30, 2024 | -15.42% |
| Mar 31, 2024 | -34.72% |
| Dec 31, 2023 | -28.12% |
| Sep 30, 2023 | 1.40% |
| Jun 30, 2023 | -29.48% |
| Mar 31, 2023 | -35.60% |
| Dec 31, 2022 | -52.99% |
| Sep 30, 2022 | 15.12% |
| Jun 30, 2022 | -48.85% |
| Dec 31, 2021 | -597.44% |
| Sep 30, 2021 | -508.68% |